England joins Sweden, Finland, Norway and other EU countries in restricting puberty blocker and hormone therapy for gender dysphoria.

Link. Stated concern is only a single outcome study with a different population than current — medication to be part of clinical trials.

“Clinics worldwide reported that the increase was largely driven by patients raised as girls.”